Molecular Cancer Therapeutics Landon Prizes for Basic and Translational Cancer Research Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, C.
Right arrow Articles by Lü, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, C.
Right arrow Articles by Lü, J.
Vol. 1, 1059-1066, October 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Distinct Effects of Methylseleninic Acid versus Selenite on Apoptosis, Cell Cycle, and Protein Kinase Pathways in DU145 Human Prostate Cancer Cells 1

Cheng Jiang2, Zaisen Wang, Howard Ganther and Junxuan Lü2,3

AMC Cancer Research Center, Denver, Colorado 80214 [C. J., Z. W., J. L.], and University of Wisconsin, Madison, Wisconsin 53706 [H. G.]

Selenium has been implicated as a promising chemopreventive agent for prostate cancer. Whereas the anticancer mechanisms have not been clearly defined, one hypothesis relates to selenium metabolites, especially the monomethyl selenium pool, generated under supranutritional selenium supplementation. To explore potential molecular targets for mediating the chemopreventive activity, we contrasted the effects of methylseleninic acid (MSeA), a novel precursor of methylselenol, versus sodium selenite, a representative of the hydrogen selenide metabolite pool, on apoptosis execution, cell cycle distribution, and selected protein kinases in DU145 human prostate cancer cells. Exposure of DU145 cells to 3 µM MSeA led to a profound G1 arrest at 24 h, and exposure to greater concentrations led to not only G1 arrest, but also to DNA fragmentation and caspase-mediated cleavage of poly(ADP-ribose) polymerase (PARP), two biochemical hallmarks of apoptosis. Immunoblot analyses indicated that G1 arrest induced by the subapoptogenic doses of MSeA was associated with increased expression of p27kip1 and p21cip1, but apoptosis was accompanied by dose-dependent decreases of phosphorylation of protein kinase AKT and extracellular signal-regulated kinase (ERK1/2) in the absence of any phosphorylation change in p38 mitogen-activated protein kinase (p38MAPK) and c-Jun NH2-terminal kinase (JNK1/2). In contrast, selenite exposure caused S-phase arrest and caspase-independent apoptotic DNA fragmentation, which were associated with decreased expression of p27kip1 and p21cip1 and increased phosphorylation of AKT, JNK1/2, and p38MAPK. Although apoptosis induction by MSeA exposure was not sensitive to superoxide dismutase added into the cell culture medium, cell detachment and DNA nucleosomal fragmentation induced by selenite exposure were greatly attenuated by this enzyme, supporting a chemical mediator role of superoxide for these processes. Despite a temporal relationship of AKT and ERK1/2 de-phosphorylation changes before the onset of PARP cleavage in MSeA-exposed cells, experiments with phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 did not show an enhancing effect of specific blocking of AKT on MSeA-induction of PARP cleavage. Taken together, exposure of DU145 cells to MSeA versus selenite induced differential patterns of cell cycle arrest and apoptosis execution as well as distinct patterns of effects on AKT, ERK1/2, JNK1/2, and p38MAPK phosphorylation and p27kip1 and p21cip1 expression. Multiple molecular pathways are likely differentially targeted by selenium metabolite pools to mediate cancer chemoprevention.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
G.-x. Li, H.-J. Lee, Z. Wang, H. Hu, J. D. Liao, J. C. Watts, G. F. Combs Jr, and J. Lu
Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite
Carcinogenesis, May 1, 2008; 29(5): 1005 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K.-M. Chen, T. E. Spratt, B. A. Stanley, D. A. De Cotiis, M. C. Bewley, J. M. Flanagan, D. Desai, A. Das, E. S. Fiala, S. Amin, et al.
Inhibition of Nuclear Factor-{kappa}B DNA Binding by Organoselenocyanates through Covalent Modification of the p50 Subunit
Cancer Res., November 1, 2007; 67(21): 10475 - 10483.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. G. Azrak, C. L. Frank, X. Ling, H. K. Slocum, F. Li, B. A. Foster, and Y. M. Rustum
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.
Mol. Cancer Ther., October 1, 2006; 5(10): 2540 - 2548.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy.
Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268.
[Abstract] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Husbeck, R. S. Bhattacharyya, D. Feldman, and S. J. Knox
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.
Mol. Cancer Ther., August 1, 2006; 5(8): 2078 - 2085.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Hu, C. Jiang, T. Schuster, G.-X. Li, P. T. Daniel, and J. Lu
Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
Mol. Cancer Ther., July 1, 2006; 5(7): 1873 - 1882.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. Last, L. Maharaj, J. Perry, S. Strauss, J. Fitzgibbon, T. A. Lister, and S. Joel
The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours
Ann. Onc., May 1, 2006; 17(5): 773 - 779.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
K. R. Martin
Targeting Apoptosis with Dietary Bioactive Agents
Experimental Biology and Medicine, February 1, 2006; 231(2): 117 - 129.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Wu, K. Zu, M. A. Warren, P. K. Wallace, and C. Ip
Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Mol. Cancer Ther., February 1, 2006; 5(2): 246 - 252.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Hu, C. Jiang, G. Li, and J. Lu
PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells
Carcinogenesis, August 1, 2005; 26(8): 1374 - 1381.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Dong, H. Zhang, A. C. Gao, J. R. Marshall, and C. Ip
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
Mol. Cancer Ther., July 1, 2005; 4(7): 1047 - 1055.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Hu, C. Jiang, C. Ip, Y. M. Rustum, and J. Lu
Methylseleninic Acid Potentiates Apoptosis Induced by Chemotherapeutic Drugs in Androgen-Independent Prostate Cancer Cells
Clin. Cancer Res., March 15, 2005; 11(6): 2379 - 2388.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Jiang, H. Hu, B. Malewicz, Z. Wang, and J. Lu
Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells
Mol. Cancer Ther., July 1, 2004; 3(7): 877 - 884.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Dong, S. O. Lee, H. Zhang, J. Marshall, A. C. Gao, and C. Ip
Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling
Cancer Res., January 1, 2004; 64(1): 19 - 22.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.